Published in Hospital Business Week, December 7th, 2008
"With our non-dialysis trials, PEARL 1 and 2, as well as our dialysis trial, EMERALD 1, fully enrolled, we have now completed enrollment in three of our four pivotal Phase 3 trials for Hematide for the treatment of anemia in chronic renal failure patients," said Arlene Morris, president and chief executive officer at Affymax....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.